Cascadian Therapeutics, Inc. (NASDAQ:CASC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “

A number of other research analysts have also commented on the stock. Cantor Fitzgerald restated a “hold” rating and set a $4.00 price target on shares of Cascadian Therapeutics in a research report on Monday, September 11th. Barclays PLC started coverage on shares of Cascadian Therapeutics in a research report on Wednesday, September 6th. They issued an “underweight” rating and a $4.00 target price for the company. ValuEngine lowered shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Cowen and Company reiterated a “buy” rating on shares of Cascadian Therapeutics in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $5.63.

Cascadian Therapeutics (NASDAQ CASC) traded down $0.08 on Tuesday, hitting $3.98. 199,500 shares of the stock were exchanged, compared to its average volume of 295,949. Cascadian Therapeutics has a 12-month low of $3.18 and a 12-month high of $7.80.

Cascadian Therapeutics (NASDAQ:CASC) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. During the same quarter in the previous year, the business earned ($0.09) EPS. sell-side analysts anticipate that Cascadian Therapeutics will post -1.25 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Cascadian Therapeutics, Inc. (CASC) Stock Rating Lowered by Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/11/14/cascadian-therapeutics-inc-casc-stock-rating-lowered-by-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of CASC. State of Wisconsin Investment Board purchased a new stake in Cascadian Therapeutics during the second quarter valued at about $104,000. New York State Common Retirement Fund purchased a new stake in Cascadian Therapeutics during the second quarter valued at about $136,000. Rhumbline Advisers purchased a new stake in Cascadian Therapeutics during the second quarter valued at about $143,000. BB&T Securities LLC purchased a new stake in Cascadian Therapeutics during the second quarter valued at about $143,000. Finally, Bank of America Corp DE boosted its position in Cascadian Therapeutics by 2,316.5% during the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 35,975 shares during the period. Institutional investors and hedge funds own 83.03% of the company’s stock.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Get a free copy of the Zacks research report on Cascadian Therapeutics (CASC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.